Healthcare

Healthcare operators undergoing balance-sheet restructuring typically prioritise debt management and shareholder engagement alongside efforts to stabilise underlying operations.

Healthcare technology companies focused on medication management and remote monitoring continue to adjust portfolios toward core, recurring-revenue segments, often supported by capital raisings to fund operations.

Early-cancer-detection diagnostics companies continue to expand pathology-network partnerships to broaden test access, while pursuing reimbursement pathways through bodies such as the Medical Services Advisory Committee.

Clinical-stage biotechs developing pain and mental-health therapies continue to rely on trial milestones and financing arrangements to progress their pipelines, withQuotationstatus and funding structure closely watched by the market.

The convertible notes being redeemed have aFace Valueof US$1,110,000 and will be redeemed for total consideration of US$1,150,000. As part of the agreement, Obsidian has also agreed not to sell Neurizon shares for a period of two months.

•Cleo Diagnostics has engaged Asuragen, the CLIA-certified laboratory of Bio-Techne Corporation, to conduct pivotal Clinical Validation for its Pre-Surgical Ovarian Cancer Test.

Medibank operates private health insurance businesses under the Medibank and ahm brands and has expanded into health-related services. During 2026, the company has continued to report on its financial performance, shareholder distributions and changes in securities holdings.